Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Peginterferon Lambda  COVID-19 treatment studies for Peg.. Lambda  C19 studies: Peg.. Lambda  Peg.. Lambda   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 0% Improvement Relative Risk Duration of symptoms -6% Change in viral load -14% c19early.com/il Jagannathan et al. NCT04331899 Peg.. Lambda RCT EARLY Favors peg.. lambda Favors control
Jagannathan, 120 patient peginterferon lambda early treatment RCT: no change in hospitalization [p=1], 6% worse recovery [p=0.76], and 14% worse viral clearance [p=0.91] https://c19p.org/jagannathan
copied to clipboard
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Jagannathan et al., Nature Communications, doi:10.1038/s41467-021-22177-1, NCT04331899 (history)
30 Mar 2021    Source   PDF   Share   Tweet
RCT 120 outpatients with mild/moderate COVID-19, showing no significant differences with peginterferon lambda-1a treatment. 180μg subcutaneous peginterferon lambda-1a. NCT04331899 (history).
risk of hospitalization, no change, RR 1.00, p = 1.00, treatment 2 of 60 (3.3%), control 2 of 60 (3.3%), day 28.
duration of symptoms, 6.4% higher, HR 1.06, p = 0.76, treatment 60, control 60, inverted to make RR<1 favor treatment.
relative change in viral load, 14.0% worse, RR 1.14, p = 0.91, treatment 60, control 60, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jagannathan et al., 30 Mar 2021, Single Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, 27 authors, average treatment delay 5.0 days, trial NCT04331899 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPeg.. LambdaAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit